Aotearoa New Zealand · Independent information vehicle
New Zealand has allowed prescribed, medically supervised ibogaine since 2009 — years before Washington began fast-tracking it. We track the science, the policy, and the capital now moving into iboga-derived medicine.
Research and public information
Ibogaine is an alkaloid from the root bark of Tabernanthe iboga, a shrub native to Central West Africa and central to the Bwiti spiritual tradition of Gabon.[Nat. Prod. Rep. 2021] It is not a recreational experience and not a quick fix.
People describe two phases: a long visionary state of dreamlike, autobiographical recall, followed by a quieter reflective period of days or weeks where the psychological work happens. For opioid dependence, the most consistent reported effect is the interruption of withdrawal and craving — an opening, not a cure. Similar reports extend to alcohol, cocaine, and methamphetamine, though the evidence is more preliminary.[Molecules 2026 scoping review]
Research also points to a biological reset. Ibogaine and its metabolite noribogaine appear to promote neuroplasticity — the brain's ability to rewire pathways — and to normalise dopamine signalling disrupted by long-term substance use.[Front. Pharmacol. 2025] In effect, the reward circuitry may be restored closer to its pre-addiction baseline, which helps explain why craving and withdrawal can diminish so rapidly after a single supervised session. In veterans with traumatic brain injury, a single magnesium-supported session produced sustained improvements in functioning, PTSD, depression and anxiety.[Nature Medicine 2024]
In New Zealand, ibogaine is an unapproved medicine that a doctor may prescribe under Section 25 of the Medicines Act.[Medsafe, Section 25] That means a prescriber, screening, and medical supervision — not mail order, and not self-treatment.
Published protocols describe cardiac assessment including ECG, medication review, and evaluation of liver and heart conditions before administration.
Research reports describe prescribing oversight, observation of cardiac measures, and structured follow-up as parts of medically supervised settings.
Psychedelic Alpha reports from ARPA-H's day-long ibogaine workshop in Washington, DC, where prospective teams connected ahead of the ASCENT-IBO funding opportunity. The agency expects combined Phase I/II clinical study designs of ibogaine for opioid use disorder, with proposals due 15 October 2026.
Psychedelic AlphaOriginal source
MedPage Today reports that trial design and participant safety dominated the FDA's public hearing on psychedelic drugs. Speakers pressed for clear standards on screening, monitoring and data before wider access.
MedPage TodayOriginal source
BioSpace reports that medical experts and stakeholders used the FDA's public hearing to press for clear safety and access standards for psychedelic therapies, with Jefferies analysts describing the tone as constructive and several speakers calling for stronger risk assessment and adverse-event monitoring in any approval.
BioSpaceOriginal source
Westword sets out which natural psychedelics are now decriminalised or regulated in Colorado and how the state framework treats substances such as ibogaine. A useful reference for how US state policy is diverging.
WestwordOriginal source
Nasdaq-listed Psyence Biomedical established a Texas subsidiary to centralise US ibogaine supply, manufacturing, regulatory documentation and any future IND filing. Subject to licensing, the entity would hold US rights to PsyLabs pharmaceutical-grade ibogaine, signalling how listed companies are structuring around US policy momentum.
Psyence BioMedOriginal source
Reuters covers the FDA's public hearing on the potential future therapeutic use of psychedelic drugs, where doctors, veterans, pharmacists and therapists urged the agency to set clear guardrails on training, screening, clinic capacity and long-term safety tracking.
ReutersOriginal source
Interviewing Americans for Ibogaine CEO Bryan Hubbard on his HHS podcast, the Health Secretary said demand — starting with veterans, at roughly 100 hours of support staff per patient — will surge once treatments are legal, and credited Trump's April executive order with breaking down barriers to evidence-based research.
Marijuana MomentOriginal source
Risk disclosure
Ibogaine prolongs the QT interval and has been associated with fatal arrhythmia, particularly alongside other drugs, electrolyte imbalance, or undiagnosed heart disease. Co-administered magnesium is being studied as a mitigation — the Stanford MISTIC protocol reported no serious cardiac adverse events under continuous monitoring — but that evidence supports careful medical settings, not unsupervised use. If you are in crisis in New Zealand, call or text 1737 to speak with a trained counsellor, free, any time.
The clinical platform · For practitioners and organisations
The platform gives clinicians structured tools for screening, vitals recording and alerting. Thresholds, protocols and workflows are configured by the treating clinician, and every flag the platform raises is reviewed and acted on by that clinician — the software supports their decisions and does not make them. Patients log symptoms and readings for their clinician to review; the software organises entries, it doesn't monitor or decide.
Structured intake and screening records configured by the treating clinician, supporting their assessment of suitability and risk before any course of care.
Symptoms and readings logged by patients are organised against protocols the treating clinician defines, keeping entries available for clinical review in one record.
Alerts raised when recorded values cross thresholds the clinician has set — surfaced for their review and judgement, never acted on by the software itself.
The platform is available under licence for clinics, research groups and sector organisations. Click the link to the app to see what is included and the licensing details.
Patients log symptoms and readings for their clinician to review; the software organises entries, it doesn't monitor or decide. Clinicians configure alert thresholds and retain responsibility for review, judgement and care. Ibogaine is available in New Zealand by prescription only.
Confidential inquiries for information, research, app licensing, or media.